Medical Marijuana (MJNA.PK+41.1%) surges after issuing a shareholder update and letter to address what it calls "recent blog articles" attacking the company. MJNA provides a lengthy defense of the CannaVest (CANV.OB) deal, recently the subject of sharp criticism from SA contributor Alan Brochstein, and says it will provide details about the transaction in its Q1 filings, due to arrive by May 15. Also, chairman/COO Michelle Sides insists she hasn't sold any shares in the company. Update: Brochstein defends himself in an Instablog.

Medical Marijuana (MJNA.PK-13%) dives after SA contributor Alan Brochstein takes aim at the company's financials once more (previous). Brochstein points out $4.5M of MJNA's Q4 sales came from an installment payment related to a $35M deal with CannaVest (CANV.OB) signed at the end of the quarter, and that CannaVest can make deal payments with its (very illiquid) stock. He also observes MJNA's Q4 sales were revised to $4.69M from a prior $5.19M (and before that, $5.1M) in its recently updated annual report.

Medical Marijuana (MJNA.PK+17.2%) rallies after reporting Q1 gross revenue of $8.45M (+66% Q/Q and +377% Y/Y) and net income of $5.52M. The company adds it plans to deliver a 24-month audit history of its financials by the end of Q2, and asserts it has "positioned itself to become fully reporting" with the SEC once the audit history is complete. MJNA plans to reports its audited Q1 financials by May 15. (PR)

Medical Marijuana (MJNA.PK+6.3%) trades higher after announcing it will begin selling its products and services in Europe, Canada, and the Caribbean. The company adds it plans to invest in local manufacturers and distributors, and hopes to bring over-the-counter products to the aforementioned markets. (PR)

Shares of Medical Marijuana Inc. (MJNA.PK-3.9%) slip today after a Seeking Alpha article calls a number of transactions (including the company's asset and inventory sale of PhytoSPHERE) as well as recent guidance into question.

Volatile Medical Marijuana (MJNA.PK-20.4%) falls to $0.23 on the pink sheets after SA authors Ashraf Eassa and Panoplos offer bearish takes. Panoplos notes that while MJNA recently valued an inventory sale/licensing deal with CannaVEST (FCLS.OB) at $35M, based on an assigned value of $5 for the CannaVEST shares issued to MJNA, the actual value of the shares could be much lower. Especially since CannaVEST recently disclosed it has "no customers," and that its sole assets consist of the items purchased in its deal with MJNA. MJNA is no stranger to double-digit swings.

Medical Marijuana Inc. ("MJNA") is the first publicly held company vested in the medical marijuana and industrial hemp markets. The company is comprised of a diversified portfolio of products, services, technology and businesses solely focused on the cannabis and hemp industries. These products...More